Viridian Therapeutics, Inc. — Q1 2024 Form 10-Q
Business context and period. This unaudited report covers the three months ended March 31, 2024. Viridian is a clinical-stage biopharmaceutical company with no approved products or product-sales revenue. Its lead programs target thyroid eye disease (TED): intravenous VRDN-001 and subcutaneous VRDN-003. The company is also developing anti-FcRn candidates VRDN-006 and VRDN-008.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Collaboration revenue | $0.072 million | $0.098 million |
| Research and development expense | $40.9 million | $50.7 million |
| General and administrative expense | $15.0 million | $21.8 million |
| Operating loss | $55.9 million | $72.5 million |
| Other income, net | $7.4 million | $4.3 million |
| Net loss | $48.5 million | $68.2 million |
| Basic and diluted loss per share | $0.79 | $1.61 |
| Operating cash used | $45.2 million | $62.0 million |
| Cash and cash equivalents | $91.6 million | $102.8 million at Dec. 31, 2023 |
| Short-term investments | $521.5 million | $374.5 million at Dec. 31, 2023 |
| Long-term debt, net | $20.3 million | $20.2 million at Dec. 31, 2023 |
| Stockholders’ equity | $582.5 million | $442.0 million at Dec. 31, 2023 |
Gross margin is not meaningful because the company has no product sales. Cash, cash equivalents, and short-term investments totaled approximately $613.2 million at quarter-end. The Hercules term loan bears interest at 8.95% as of March 31, 2024, is due October 1, 2026, and is secured by substantially all borrower assets other than intellectual property.
Changes versus the prior comparable period
- Net loss narrowed by $19.6 million, chiefly as operating expenses fell and interest income rose. R&D declined $9.8 million and G&A declined $6.8 million.
- Lower R&D reflected, among other items, the absence of a $15.0 million prior-year upfront payment for subcutaneous delivery systems and lower manufacturing and preclinical costs. These were partly offset by $9.1 million of higher clinical-trial costs, mainly for THRIVE and THRIVE-2.
- G&A was lower primarily because of reduced severance and share-based compensation related to former executives. Q1 2024 included $12.7 million of share-based compensation, including $3.5 million associated with accelerated vesting for former executives.
- Operating cash use improved by $16.8 million year over year. Investing cash use increased to $143.0 million, primarily reflecting net purchases of short-term investments, rather than operating investment or capital expenditure. Financing provided $177.1 million, largely from equity issuance.
- Viridian raised approximately $150.0 million gross in a January public offering and received approximately $35.2 million net from ATM sales during the quarter. Common shares outstanding increased from 54.0 million at year-end to 63.8 million at March 31; some Series A preferred shares also converted to common stock.
Outlook, commentary, and risks
- Management expects existing cash, cash equivalents, and investments to fund its clinical development plan into the second half of 2026. The liquidity note separately states that resources are expected to cover operating expenses and capital needs for at least twelve months from the financial-statement issuance date. The company expects continued losses and will require additional capital over time.
- Management expects R&D spending to increase as programs advance. No specific revenue or earnings guidance is provided.
- VRDN-001 Phase 3 THRIVE topline results were expected in September 2024 and THRIVE-2 results by year-end 2024. The company was enrolling STRIVE to support a planned 300-patient safety database and anticipated filing a BLA in the second half of 2025.
- Viridian expected to initiate a global pivotal VRDN-003 program in mid-2024. For FcRn candidate VRDN-006, it planned an IND filing by year-end 2024 and expected healthy-volunteer data in the second half of 2025.
- Key uncertainties include trial safety, efficacy and enrollment; regulatory requirements and timing; competition; and reliance on third parties for clinical work and manufacturing. The filing highlights single-source manufacturing, a technology transfer for VRDN-001, and exposure to foreign suppliers and potential U.S. restrictions affecting China-based service providers, including WuXi. The FDA had suspended further review of the company’s VRDN-001 orphan-drug-designation application pending additional information.
- Development and commercial milestone, royalty, and other contingent obligations could require future payments, but timing and likelihood were not estimable. The company disclosed related-party arrangements with Zenas BioPharma and Paragon. Management reported effective disclosure controls at a reasonable level of assurance and no material legal proceedings.
Important facts for investors to verify
- Whether THRIVE and THRIVE-2 results, the VRDN-003 pivotal-program timeline, and the planned VRDN-001 BLA timing were achieved or changed.
- Whether the expected runway into the second half of 2026 remains supportable as trial costs rise, and what additional financing may be required.
- Progress and risks in manufacturing technology transfer, supplier redundancy, and exposure to China-related regulatory or trade actions.
- Potential dilution from future equity issuance, preferred-stock conversion, options, and other securities; also review the Hercules loan’s collateral, covenants, and repayment terms.
- Any updated regulatory feedback on the 300-patient safety database and orphan-drug designation, and any changes to contingent license and collaboration obligations.